Smoking Cessation Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SBP-9330 (With a Nested Food-Effect Arm) After Oral Administration in Healthy Subjects
Verified date | March 2024 |
Source | Camino Pharma, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single center, first-in-human, randomized, double-blind, placebo-controlled, Single-Ascending Dose (SAD) / Multiple-Ascending Dose (MAD) study incorporating a food-effect cohort.
Status | Completed |
Enrollment | 90 |
Est. completion date | March 6, 2023 |
Est. primary completion date | March 6, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Provision of written informed consent prior to the initiation of any protocol-specific procedures 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Healthy male or female subject = 18 and = 55 years of age 4. Body mass index (BMI) = 18.5 kg/m2 and = 32.0 kg/m2 5. Body weight = 50.0 kg at Screening 6. A female subject must meet at least one of the following criteria: a. Is of childbearing potential and agrees to use an acceptable contraceptive method. b. Is of non-childbearing potential, defined as surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is in a postmenopausal state (i.e., at least 1 year without menses prior to the first study drug administration without an alternative medical condition and confirmed with a serum follicle-stimulating hormone [FSH] > 40 IU/L at Screening) 7. Male subjects, if not surgically sterilized, must agree to use adequate contraception and not donate sperm from the first admission to the CRU until 90 days after the last study drug administration. 8. Part A and B only: Never- or nonsmoker (a nonsmoker is defined as someone who completely stopped using nicotine products for at least 2 years prior to the first study drug administration) 9. Have no clinically significant medical or mental health conditions captured in the medical history or evidence of clinically significant findings on the physical examination and/or ECG, as determined by an Investigator 10. No clinically significant abnormalities in blood pressure, heart rate, body temperature and respiratory rate and no evidence of orthostatic hypotension or postural tachycardia at Screening. Part C Only: 11. Are current tobacco cigarette smokers who smoke an average of 10 or more cigarettes per day in the 30 days prior to Screening 12. Expired breath CO level =10 parts per million (ppm) at Screening and prior to the first study drug administration 13. Positive test result for cotinine at Screening and prior to the first study drug administration 14. Are not motivated to try to quit smoking from Screening through 30 days from the first study drug administration Exclusion Criteria: 1. Female who is lactating 2. Female who is pregnant according to the pregnancy test at Screening or prior to the first study drug administration 3. Female who is planning to become pregnant during this study or within 90 days after the last study drug administration 4. Male with female partner who is pregnant, lactating, or planning to become pregnant during this study or within 90 days after the last study drug administration 5. Poor venous access as determined by an Investigator at Screening 6. History of significant hypersensitivity to SBP-9330 or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs 7. Presence of any medical condition that, in the opinion of an Investigator, poses an unacceptable risk to the subjects 8. Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug absorption 9. Evidence or history of clinically significant cardiovascular, pulmonary, hematologic, psychiatric (including mood and substance use disorders), neurological (including migraines, seizures, and epilepsy), endocrine, renal, hepatic, gastrointestinal, immunologic or dermatologic disease 10. History of malignancy within the past five years, except for successfully treated basal cell carcinoma of the skin 11. History of suicidal ideation or suicidal behavior as per the C-SSRS questionnaire administered at Screening 12. Evidence or history of significant psychiatric disease or any DSM-5 disorder as assessed by the Mini International Neuropsychiatric Interview (M.I.N.I.) administered at Screening 13. Routine or chronic use of more than three grams of acetaminophen daily 14. Strenuous activity, sunbathing, and contact sports within 48 hours prior to (first) admission to the CRU 15. Current alcohol consumption exceeding two standard drinks per day on average (1 standard drink=10 grams of alcohol) for male subjects and one standard drink per day on average for female subjects 16. History of alcohol or drug (other than caffeine) use disorder within 12 months prior to Screening 17. Any clinically significant illness in the 28 days prior to the first study drug administration 18. QTcF interval (QT interval corrected for heart rate according to Fridericia) > 450 ms for males and > 470 ms for females at Screening or on Day -1 19. Parts A and B only: Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first drug administration 20. Positive test results for HIV-1/HIV-2 antibodies, hepatitis B surface antigen or hepatitis C antibody 21. Consumption of any prescription drugs (with the exception of hormonal contraceptives or hormone replacement therapy) or over-the-counter medications and nutrients known to modulate cytochrome P450 (CYP450) enzymes activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville [blood] orange products) or St. John's Wort within 14 days prior to the first study drug administration 22. Consumption of other prescription and over-the-counter medication not specifically excluded by Exclusion Criterion 21 including health supplements and herbal remedies within 7 days prior to the first study drug administration (an exception is made for paracetamol [acetaminophen], which is allowed up to admission to the clinic). 23. Any other clinically significant abnormalities in laboratory test results at Screening that would, in the opinion of an Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data 24. Intake of an investigational product in the 30 days or 5 half-lives (whichever is longer) prior to Screening 25. Inclusion in a previous cohort of this clinical study 26. Employee of the contract research organization (CRO) or the Sponsor. 27. Blood donation (excluding plasma donation) of approximately 500 mL within 56 days prior to Screening 28. Plasma donation within 7 days prior to Screening Part C Only: 29. History of generalized rash reaction to any drugs 30. Positive test result (except cotinine) for alcohol and/or drugs of abuse at Screening or prior to the first study drug administration 31. Use of smoking cessation aids (NRT, bupropion, or varenicline) within 30 days prior to the first study drug administration 32. Unable to abstain from smoking tobacco cigarettes for at least 1 hour before and 2 hours after study drug administration 33. Unable to abstain from using nicotine-containing products other than tobacco cigarettes (e.g., pipes, cigars, e-cigarettes or vapes, nicotine topical patches, nicotine gum, or nicotine lozenges) during the study |
Country | Name | City | State |
---|---|---|---|
United States | Altasciences Clinical Kansas, Inc | Overland Park | Kansas |
Lead Sponsor | Collaborator |
---|---|
Camino Pharma, LLC | National Institute on Drug Abuse (NIDA), Sanford Burnham Prebys Medical Discovery Institute, University of California, San Diego |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Expired Carbon Monoxide (ECO) Level | Expired breath CO was measured with a Bedfont Smokerlyzer™ | Daily from Screening through Day 14 | |
Other | Plasma Cotinine Level | Blood samples were collected to measure plasma cotinine levels | Predose, Day 7 and Day 14 | |
Other | Number of Cigarettes Smoked | A daily smoking log was kept to document the number of cigarettes smoked | Daily from Screening through Day 14 | |
Other | Minnesota Nicotine Withdrawal Scale (MNWS) | A self-report measure used to monitor symptoms of tobacco withdrawal. | Screening through Day 14 | |
Other | Questionnaire on Smoking Urges - Brief Version (QSU-Brief) | A self-report questionnaire used to measure cravings to smoke. | Screening through Day 15 | |
Primary | Number of Treatment-Emergent Adverse Events [Safety and Tolerability] | Number of drug-related adverse events as determined by clinically significant changes in vital signs, physical examination findings, ECG parameters, C-SSRS questionnaire results, and clinical laboratory results | Part A: 8 days Part B: 21 days Part C: 21 days | |
Secondary | Pharmacokinetics of SBP-9330: Cmax | Maximum observed concentration (Cmax) | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: Tmax | Time to reach maximum observed concentration (Tmax) | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: AUC 0-24 | Area under the concentration time curve from time 0 (dose administration) to 24 hours | PK samples were obtained at selected timepoints from pre-dose until 24 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: AUC 0-T | Area under the concentration time curve from time 0 (dose administration) to the time of last quantifiable concentration | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: AUC 0-8 | Area under the concentration time curve extrapolated to infinity | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: T½ | Terminal elimination half-life | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: CL/F | Apparent total clearance | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: Vz/F | Apparent volume of distribution | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: C Trough | Observed concentration at the end of the dosing interval | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: Ct | Concentration at the end of the dosing interval. | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: AUCt | Area under the concentration time curve over the dosing interval at steady state, calculated from 0 to 24 hours (dosing interval) | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: T½, Eff | Effective half-life | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: CL/Fss | Apparent total clearance at steady state | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: Vz/Fss | Apparent volume of distribution at steady state | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: RAC(Cmax) | Accumulation ratio evaluated by comparing Day 14 Cmax to Day 1 Cmax | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose | |
Secondary | Pharmacokinetics of SBP-9330: RAC(AUC) | Accumulation ratio evaluated by comparing Day 14 AUCt to Day 1 AUC0-24 | PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT04617444 -
The ESTxENDS Trial- Substudy on Effects of Using Electronic Nicotine Delivery Systems (ENDS) on Olfactory Function
|
N/A | |
Completed |
NCT02796391 -
Facilitating Smoking Cessation With Reduced Nicotine Cigarettes
|
Phase 2 | |
Completed |
NCT03397511 -
Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City
|
N/A | |
Not yet recruiting |
NCT05188287 -
A Culturally Tailored Smartphone Application for African American Smokers
|
N/A | |
Recruiting |
NCT05264428 -
The Effect of Honey on Lessening the Withdrawal Symptoms
|
N/A | |
Recruiting |
NCT05846841 -
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
|
N/A | |
Completed |
NCT04133064 -
Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study
|
N/A | |
Completed |
NCT03187730 -
Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants
|
Phase 4 | |
Completed |
NCT03474783 -
To Explore the Factors Affecting the Effectiveness of Smoking Cessation
|
N/A | |
Completed |
NCT04635358 -
Feasibility Study of Smoking Cessation for the Staff of a Hospital Center
|
N/A | |
Terminated |
NCT03670264 -
BE Smokefree: Behavioral Economics Incentives to Engage Adolescents in Smoking Cessation
|
N/A | |
Not yet recruiting |
NCT06307496 -
VIDeOS for Smoking Cessation
|
N/A | |
Completed |
NCT02997657 -
Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT02905656 -
Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit
|
N/A | |
Completed |
NCT03206619 -
A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
|
||
Completed |
NCT02562521 -
A Smoking Cessation Intervention for Yale Dining Employees
|
Phase 4 | |
Completed |
NCT02239770 -
Pharmacokinetics of Nicotine Film in Smokers
|
N/A | |
Recruiting |
NCT02422914 -
Benefits of Tobacco Free Cigarette
|
N/A |